

**THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.**

**THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.**

**UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.**

**genedrive plc  
("genedrive" or the "Company")**

**Result of General Meeting**

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that at the General Meeting, held today, none of the resolutions were passed on a poll vote.

The resolutions were unanimously recommended to shareholders by the Board as the Equity Financing was the only certain financing option available to the Company. As a result of the resolutions not being passed the Conditional Placing and Retail Offer will not complete, and the Company does not have authority to issue any warrants in connection with the Equity Financing announced on 23 September 2025.

As highlighted in the Company's announcement of 6 October 2025, the Company has funding through to the end of 2025, however the uncertainty that this vote creates may impact negatively the Group's operations which, in the absence of additional funding being made available, could accelerate the timeline on which the Directors have to take action to protect the position of creditors.

Finally, whilst the Company continues to engage proactively with David Nugent, a 15.1% shareholder in the Company (including via a limited company), there has been no material change to the status of discussions with that shareholder.

Further announcements will be made as required.

For information, details of poll voting are shown below:

Resolution	Votes For (including those giving the Chair discretion)	Votes For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Vote Withheld
1	124,342,285	39.9	187,204,980	60.1	34,384,955
2	123,618,410	39.7	187,928,855	60.3	34,384,955
3	123,890,904	39.8	187,656,361	60.2	34,384,955
4	122,985,041	39.5	188,562,224	60.5	34,384,955

The full text of each of the resolutions is set out in the notice of General Meeting, copies of which are available on the Company's website ([www.genedriveplc.com](http://www.genedriveplc.com)).

The Company's issued ordinary share capital remains 1,024,895,408 Ordinary Shares. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the applicable announcement of the Fundraising made by the Company on 23 September 2025.

**Dr Ian Gilham, Non-executive Chairman of genedrive plc, said:** *"Shareholders have comprehensively voted against this financing proposal which would have provided the Company with a cash runway through to Q2/Q3 2026 plus the potential of further funding from the exercise of warrants. In light of the significant efforts that have already gone into raising additional funding leading to this proposal the Company is cautious about the prospects of securing further capital on terms more favorable to the deal which necessitated this shareholder vote. However the Board would continue to welcome and encourage any alternative financing proposals from shareholders or other interested parties that could support its ongoing growth and strategic objectives."*

For further details please contact:

**Enquiries:**

**genedrive plc**  
Dr Gino Miele (CEO)  
Russ Shaw (CFO)

+44 (0) 161 989 0245

**Peel Hunt LLP - Nominated Adviser, Broker and Joint Bookrunner**  
James Steel (Investment Banking)  
Sohail Akbar / Nicholas Wilks (ECM)

+44 (0) 20 7148 8900

**Allenby Capital Limited - Joint Broker and Joint Bookrunner to the Placing**  
Nick Athanas / Vivek Bhardwaj (Corporate Finance)  
Amrit Nahal / Kelly Gardiner (Sales & Corporate Broking)

+44 (0)20 3394 2973  
info@allenbycapital.com

**Walbrook PR - Financial PR & IR Adviser**  
Anna Dunphy

+44 (0) 20 7933 8780  
or genedrive@walbrookpr.com

**About genedrive plc (<http://www.genedriveplc.com>)**

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMGPGMCUUPAUBA